Company: LCTX
Filing Date: 2025-08-26
Form Type: 8-K
Source: 0000950170-25-111319
Chunk: 0

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-08-26
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On August 26, 2025, Lineage Cell Therapeutics, Inc. (“we,” “us,” “our,” the “ Company,” or “ Lineage”) issued a press release announcing that it entered into a multi-year research collaboration agreement with William Demant Invest 2 Aps (“ WDI”) to advance the preclinical development of Lineage’s auditory neuronal cell transplant program, ReSonanceTM(ANPI), for the treatment of hearing loss. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information in this Item 7.01 and in Exhibit 99.1 to this report is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.